Innovation Pharmaceuticals Inc (IPIX)

[kfcyahoo]

We'll see. The following company comment from the 1/22/17 pr regarding patients being treated with B for UC sounds quite similiar to compay comments after the p2b trial but before final review.

"Site investigators report enthusiastic feedback from patients currently receiving treatment in the second cohort with Brilacidin at 100 mg daily (by retention enema) for six weeks —comments included how the treatment already has greatly improved or eliminated their symptomatic complaints, daily functioning and overall quality of life. There is significant interest by new patients wishing to participate in the third (final) cohort once enrollment opens."